Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study

Melissa A. Runge-Morris, Merrill S. Kies, Everett Vokes, Richard Blough, Linda Weidner, Richard Knop, Kendrith Rowland

Research output: Contribution to journalArticlepeer-review

Abstract

Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.

Original languageEnglish (US)
Pages (from-to)269-273
Number of pages5
JournalInvestigational New Drugs
Volume7
Issue number2-3
DOIs
StatePublished - Jul 1989
Externally publishedYes

Keywords

  • blood pressure
  • complete blood count
  • hematocrit
  • homoharringtonine
  • squamous cell carcinoma of the head and neck
  • white blood cell count

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study'. Together they form a unique fingerprint.

Cite this